Could TIM3 be a viable target of immunotherapy (IO) in pediatric glioma? Hear Shashwat Tripathi (Shashwat T.) from the Northwestern University - The Feinberg School of Medicine & Lurie Cancer Center discuss how whole transcriptome and single-cell sequencing, mouse models, and flow cytometry point to TIM3 in BRAF-fused MAPK-driven pilocytic astrocytomas. https://lnkd.in/ga9tAZ8 #SNO2024
Caris Life Sciences
生物技术研究
Irving，Texas 59,445 位关注者
Fulfilling the promise of precision medicine through quality and innovation.
关于我们
Caris Life Sciences? (Caris) is the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia and other international markets.
- 网站
-
https://www.carislifesciences.com
Caris Life Sciences的外部链接
- 所属行业
- 生物技术研究
- 规模
- 1,001-5,000 人
- 总部
- Irving，Texas
- 类型
- 私人持股
- 创立
- 1996
- 领域
- Biotechnology、Molecular Profiling、Genomics、Personalized Medicine、Diagnostics、Theranostics、Panomics、Precision Medicine和Comprehensive Genomic Profiling
地点
Caris Life Sciences员工
动态
-
Caris Life Sciences is pleased to announce the appointment of Dr. Jeff Vacirca, CEO and Chairman of the Board of New York Cancer & Blood Specialists, to our Board of Directors. “We are thrilled to welcome Jeff to our board,” said David Dean Halbert, DSc (h.c.), Chairman, Founder and CEO of Caris. “His extensive leadership across cancer care delivery, therapeutic development and patient/legislative advocacy, as well as his entrepreneurial experience, will bring an invaluable perspective to our board of directors.” Learn more: https://lnkd.in/g6Ti23Ra
-
-
Join Jaclyn Hechtman, MD, as she explores the power of whole blood profiling with Caris Assure to distinguish between clonal hematopoiesis (CH) and tumor mutations. By analyzing both plasma and Buffy coat, this approach provides clinicians with the comprehensive molecular intelligence needed to develop treatment plans that may help improve patient outcomes. #AMPath24 https://lnkd.in/gZm92Zdg
-
-
We are proud to announce that our liquid biopsy assay, Caris Assure, has been named the Molecular Diagnostics Solution of the Year by BioTech Breakthrough. This recognition is a testament to our relentless commitment to advancing cancer care and the incredible work of our talented team.
-
Caris Life Sciences will be exhibiting at the International Society of Liquid Biopsy (ISLB) Annual Congress in Denver. Stop by booth 105 to learn about our groundbreaking liquid biopsy solution, Caris Assure, and learn how we’re working to help transform patient care. Don’t miss out—let’s connect.?#ISLB24 https://lnkd.in/gZm92Zdg
-
-
Join our expert panel for an in-depth discussion on how Caris Assure detects clonal hematopoiesis and germline variants and the importance of differentiating these from somatic solid tumor variants. Register now: https://lnkd.in/gSSivpRd Speakers: Theodore Nicolaides, MD – Senior Medical Director, Caris Life Sciences Jaclyn Hechtman, MD – Medical Director Pathology, Caris Life Sciences
此处无法显示此内容
在领英 APP 中访问此内容等
-
Lumea is thrilled to announce a new partnership with Caris Life Sciences? to expand access to advanced molecular profiling directly within our BxLink? platform! This integration provides urologists with seamless access to comprehensive exome and transcriptome sequencing, empowering them to make faster, data-driven decisions for urological cancer treatment. Here's what this means for healthcare providers: -Integrated Sequencing: Caris molecular profiling services available directly within BxLink, simplifying diagnostics. -Streamlined Workflow: Fewer clicks, reduced data entry, and real-time tracking of diagnostic progress. -Enhanced Precision: Support for informed, efficient treatment planning at the point of care. Learn more about this exciting step forward in digital pathology and precision healthcare: https://lnkd.in/gN428F_C #DigitalPathology #PrecisionMedicine #Urology #HealthcareInnovation #CarisLifeSciences
-
-
Join us at the AMP 2024 Annual Meeting in Vancouver. Stop by the Caris Life Sciences booth to network, learn about our latest advancements, and share insights with our team. Let’s connect and shape the future of precision medicine together. https://ow.ly/23q850U0S4B #AMPath24
-
-
What do the tumor-immune microenvironments (TIME) of different subtypes of liposarcoma (LPS) suggest about their potential response to immunotherapy? Hear Dr. Julie Grossman from the University of Miami and Jackson Memorial Hospital discuss DNA, RNA, and protein data from 344 LPS cases. #CTOS2024 https://lnkd.in/ga9tAZ8
-
-
Could immune checkpoint inhibitors be useful in sarcomas with DNA repair pathway mutations? Hear Dr. Kurt Statz-Geary from the University of Miami and Jackson Memorial Hospital discuss tumor molecular profiles from 5,309 sarcoma patients, including 3,612 with whole transcriptome sequencing (WTS). #CTOS2024 https://lnkd.in/ga9tAZ8
-